CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a biotech pioneer using gene-editing technology to develop potential cures for serious blood diseases and cancers.
Is CRISPR Therapeutics AG a good stock for a UK beginner?
The honest version: CRISPR Therapeutics is a biotech pioneer using gene-editing technology to develop potential cures for serious blood diseases and cancers.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
The company becomes a leader in a new era of genetic medicine.
Technological obsolescence or inability to scale production.
What does CRISPR Therapeutics AG do?
The company uses a revolutionary tool called CRISPR to 'edit' DNA, aiming to fix genetic errors that cause life-altering illnesses. Income flows from partnering with larger pharmaceutical firms to bring these complex treatments to market, though they are still in the early stages of turning a profit. Much depends on their progress in winning regulatory approval so their therapies can reach patients.
On our factor screen it looks strongest on growth and value, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 69% over the year
- !Thin profits - turns only about 0% of sales into profit
- Growth screens high (95/100)
- Leading position in cutting-edge gene-editing technology
- Strong revenue growth trajectory
- Strategic partnerships with established pharmaceutical giants
- Quality screens low (22/100)
- Momentum screens low (18/100)
- Income screens low (16/100)
- High dependency on successful clinical trial outcomes
- Strict and unpredictable regulatory hurdles
What do CRISPR Therapeutics AG's numbers mean?
How much money does CRISPR Therapeutics AG make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does CRISPR Therapeutics AG pay a dividend?
No - CRISPR Therapeutics AG doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does CRISPR Therapeutics AG report earnings, and how did recent quarters go?
CRISPR Therapeutics AG is next scheduled to report on about 2026-08-10 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-04 | $-1.23 | $-1.28 | Missed -4% |
| 2026-02-12 | $-1.23 | $-1.37 | Missed -12% |
| 2025-11-10 | $-1.29 | $-1.17 | Beat +9% |
| 2025-08-04 | $-1.40 | $-1.29 | Beat +8% |
| 2025-05-06 | $-1.28 | $-1.58 | Missed -24% |
| 2025-02-11 | $-1.19 | $-0.44 | Beat +63% |
Across the last 6 quarters here, CRISPR Therapeutics AG came in ahead of what analysts expected 3 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for CRISPR Therapeutics AG?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of CRISPR Therapeutics AG?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Leading position in cutting-edge gene-editing technology
- Strong revenue growth trajectory
- Strategic partnerships with established pharmaceutical giants
- Currently not profitable with zero net margins
- High share price volatility compared to the broader market
- No dividend payments for shareholders
- High dependency on successful clinical trial outcomes
- Strict and unpredictable regulatory hurdles
- Significant cash burn required for ongoing research and development
The write-up's own warning lights — if these start happening, the case above changes.
- A permanent halt to clinical trials for their lead candidates
- A major shift in how gene therapies are regulated or funded globally
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.